MET and non-small cell lung carcinoma: As TrkA was the MET-unrelated kinase most strongly inhibited by tepotinib at 0.1 μmol/L, and TrkA (NTRK1) is a relevant target in NSCLC, an in vitro study evaluated whether tepotinib at ≥0.1 μmol/L had antitumor activity against TrkA (NTRK1)-dependent, TPM3-NTRK1–expressing, colorectal cancer KM-12 cells (33).